January 2013 | Oncology & Biotech News

February 18, 2013

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

February 18, 2013

For patients battling a disease recurrence, results from tests in mice can translate to novel treatment approaches for individual cancer patients.

February 13, 2013

Several updates highlighted at the 2012 American Society of Hematology Annual Meeting as well as other developments.

February 11, 2013

It has always been our job as cancer care physicians to guide the patient, even when our guidance is not what one would like to hear.

February 07, 2013

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.

February 06, 2013

Community practice viability may hinge on understanding and adapting to more aggressive payer involvement

February 05, 2013

Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.

February 04, 2013

A new drug screening method revealed that cholesterol-reducing statin drugs used in combination with cyclin-dependent kinase inhibitors might serve as an effective treatment approach for certain types of melanoma.

February 01, 2013

Discussion with Edith Perez, MD, about key research presented at SABCS, ongoing developments in breast cancer treatment, and the current focal areas of her research.

January 30, 2013

The oral diabetic medication metformin may help improve survival in patients with ovarian cancer, according to the results of a retrospective case-control study.

January 30, 2013

Research from the Ohio State University Comprehensive Cancer Center suggests that chlorambucil may be better than fludarabine in treating older patients with CLL, and that rituximab is beneficial regardless of age.

January 29, 2013

Researchers have discovered that the oncogenic function of a particular protein in CRPC can cause the cancer to spread without stimulation by male hormones.